Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=174682&wire=4 MLTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL- 17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit ...